Filter News
Area of Research
- (-) Neutron Science (6)
- Biological Systems (1)
- Biology and Environment (25)
- Biology and Soft Matter (1)
- Clean Energy (17)
- Climate and Environmental Systems (1)
- Computer Science (1)
- Fusion and Fission (2)
- Fusion Energy (1)
- Materials (12)
- Materials for Computing (1)
- National Security (3)
- Nuclear Science and Technology (1)
- Quantum information Science (1)
- Supercomputing (16)
News Topics
- (-) Biomedical (1)
- (-) Environment (4)
- (-) Quantum Science (1)
- Artificial Intelligence (1)
- Bioenergy (1)
- Biology (2)
- Clean Water (1)
- Computer Science (3)
- Cybersecurity (1)
- Decarbonization (1)
- Energy Storage (4)
- Frontier (1)
- Machine Learning (1)
- Materials (3)
- Materials Science (3)
- National Security (1)
- Neutron Science (18)
- Nuclear Energy (1)
- Physics (2)
- Security (1)
- Space Exploration (1)
- Summit (1)
Media Contacts
Paul Langan will join ORNL in the spring as associate laboratory director for the Biological and Environmental Systems Science Directorate.
Scientists at ORNL used neutron scattering to determine whether a specific material’s atomic structure could host a novel state of matter called a spiral spin liquid.
Illustration of the optimized zeolite catalyst, or NbAlS-1, which enables a highly efficient chemical reaction to create butene, a renewable source of energy, without expending high amounts of energy for the conversion. Credit: Jill Hemman, Oak Ridge National Laboratory/U.S. Dept. of Energy
An international team of scientists, led by the University of Manchester, has developed a metal-organic framework, or MOF, material
Researchers at the Department of Energy’s Oak Ridge National Laboratory, Pacific Northwest National Laboratory and Washington State University teamed up to investigate the complex dynamics of low-water liquids that challenge nuclear waste processing at federal cleanup sites.
OAK RIDGE, Tenn., March 20, 2019—Direct observations of the structure and catalytic mechanism of a prototypical kinase enzyme—protein kinase A or PKA—will provide researchers and drug developers with significantly enhanced abilities to understand and treat fatal diseases and neurological disorders such as cancer, diabetes, and cystic fibrosis.